Generis, creator of the cloud data, content, and business process management platform CARA, today announced that Polpharma has selected the CARA™ Life Sciences Platform for Pharmacovigilance Case Management and ensuring E2B R3 Compliance.
Polpharma, founded in 1935, is the leader of the Polish pharmaceutical market and one of the leading drug manufacturers in the region of Central and Eastern Europe. They offer modern drugs, substances, and innovative solutions for patients and business partners from around the world.
The Generis team impressed us with their efficient project planning and willingness to work towards our requirements; Generis are truly working with us to make sure the CARA platform meets all of our needs.
Like many other companies at the moment, Polpharma was looking for a platform which would ensure E2B R3 compliance and provide capabilities for PV case management. With the CARA Life Sciences Platform, PV cases can be created in CARA from different input sources (XML input, emails, manual entry), and then processed to closure, providing full traceability and reporting.
Read More: SalesTechStar Interview With Pedro Souza, Vice President Of Customer Care At SmartBear
“We were looking for a system which would give us control and compliance,” said Krzysztof Karpiński, QPPV, Chief of PV & MI, Polpharma, “but it was the flexibility and configurability of CARA which we appreciated the most. The Generis team impressed us with their efficient project planning and willingness to work towards our requirements; Generis are truly working with us to make sure the CARA platform meets all of our needs.”
The CARA Life Sciences Platform offers companies the opportunity to unify their entire R&D landscape with the unique ‘information lake’ concept for managing data, documents, and other forms of content. This allows users to input the information once and easily re-use it, which reduces duplication of work and allows for greater efficiency across the organisation.
Read More: How Buyer-led Selling Optimizes the Experience
“We are excited to be able to welcome a forward-thinking company like Polpharma to our customer family,” commented James Kelleher, CEO of Generis, “as well as to expand our client base in the area of Safety and PV Case Management, especially with companies who are looking to consolidate their numerous separate systems onto a single platform. For professionals working within Safety, one of the key benefits is the ability to effectively connect Safety data with their Clinical and Regulatory information, something made easy with the CARA Life Sciences Platform.”
